Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like V*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	gross_sales_us_dollars	gross_sales_us_dollars_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000450	Vericel Corporation	04/29/2025	69866103005	MACI®; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 1 BAG in 1 BOX (69866-1030-5) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-4) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-3)	03/03/2025	5157.00	65822.00	11/25/2033	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-01. The product was relabeled and given a new NDC # 69866-1030-05 with a market entry date 05/10/2021.
Rx0000450	Vericel Corporation	04/29/2025	69866103008	MACI®; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX (69866-1030-8) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6)	03/03/2025	10314.00	131644.00	11/25/2033	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021.
Rx0000155	Vertical Pharmaceuticals, LLC	03/17/2025	68025005230	Corvite 150 - Iron Supplement multivitamin/ multimineral, Oral Tablets, 1 Package with 30 Count	01/01/2025	17.56	194.95	04/21/2029	Single Source Drug	None	None	None	1	Price increase for this product is based on the increase in the cost of materials and goods that we must purchase in order to manufacture and distribute the product	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000155	Vertical Pharmaceuticals, LLC	03/17/2025	68025006030	Corvite Fe- Iron Supplement, Oral Tablet, 1 package with 30 count tablets	01/01/2025	23.10	256.43	04/27/2029	Single Source Drug	None	None	None	1	Price increase for this product is based on the increase in the cost of materials and goods that we must purchase in order to manufacture and distribute the product	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000066	ViiV Healthcare	04/04/2025	49702024613	Dovato Oral Tablet 50-300 MG 30 tablets per bottle	01/01/2025	119.06	3095.69	01/24/2031	Single Source Drug	None	None	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_1 YEAR PRIOR TO ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	04/04/2025	49702024213	Juluca Oral Tablet 50-25 MG, 30 tablets per bottle	01/01/2025	140.49	3652.73	09/05/2038	Single Source Drug	None	None	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_1 YEAR PRIOR TO ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	04/04/2025	49702023113	Triumeq Oral Tablet 600-50-300 MG, 30 tablets per bottle	01/01/2025	149.90	3897.42	06/08/2030	Single Source Drug	None	None	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_1 YEAR PRIOR TO ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	04/04/2025	49702025837	Triumeq PD Oral Tablet Soluble 60-5-30 MG, 90 tablets per bottle	01/01/2025	44.97	1169.23	06/08/2030	Single Source Drug	None	None	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_1 YEAR PRIOR TO ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.